Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — AusBiotech Conference 2019
13 slides from Optiscan Imaging's conference presentation, Oct 31, 2019
Slide 1: Optiscan Presentation at AusBiotech Conference
ASX Announcement 31 October 2019 Optiscan Presentation at AusBiotech Conference Optiscan Limited (ASX: OIL, Optiscan) provides the attached investor presentation which will be presented today at the AusBiotech Conference. The Company also advises that a link to a recent interview carried out by Proa
Slide 2: Optiscan Imaging Ltd (ASX:OIL)
Optiscan Imaging Ltd (ASX:OIL) Enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection
Slide 3: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 31 October 2019. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor ma
Slide 4: Notice
Notice Not an offer or financial product advice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure doc
Slide 5: Corporate Snapshot
Corporate Snapshot Board Total Securities on Issue Darren Lurie – Executive Chairman ▪ 470,178,800 Ordinary Shares B.LLB (Hons) and B.COM (Hons) ▪ 2,600,000 Performance Rights Former Group CFO and Head of Corporate Development for EduCo ▪ 25,600,000 unlisted options International (an investee compan
Slide 6: From Laboratory Benchtop to Operating Theatre
From Laboratory Benchtop to Operating Theatre Desktop Confocal Microscope Optiscan’s confocal device Successfully miniaturised high resolution benchtop confocal microscope into hand-held probe with 4.0mm diameter providing unique microscopic imaging for clinicians. Underpinned by multi-patented tech
Slide 7: Optiscan Technology Enables “Real Time Virtual Biopsy”
Optiscan Technology Enables “Real Time Virtual Biopsy” Optiscan technology changing pathology and surgical cancer practice Screening, early cancer Tumour margin detection diagnosis and targeted in cancer surgery biopsies Images available instantaneously compared to waiting 3-4 days for the return of
Slide 8: Cancer Cases Worldwide – Addressable Market
Cancer Cases Worldwide – Addressable Market 18.1M total 297,000 450,000 Oral and 570,000 2.1M Breast 3.4M Upper and Brain and Cervix& cancer cases CNS cancer Oropharyng eal cancer Uterus cancer cancer cases Lower GI cancer cases p.a. cases p.a. p.a. p.a. cases p.a. cases p.a. Carl Zeiss Application
Slide 9: Brain Cancer – Collaboration with Carl Zeiss Meditec AG
Brain Cancer – Collaboration with Carl Zeiss Meditec AG ▪ United States (FDA 510(k)) and European (CE Mark) approvals obtained ▪ CONVIVO “Digital Biopsy Tool” (Check) an integral part of the 3 step Zeiss Tumour Workflow in Neurosurgery ▪ Sales expected in first few months of FY20 ▪ https://www.zeiss
Slide 10: Oral Cancer – Seeking FDA Approval
Oral Cancer – Seeking FDA Approval PROGRESS Regulatory • Seeking FDA 510(k) Clearance for its system for use in Oral Cancer Screening and/or Surgery Approvals • Working with US based regulatory advisers Product • Engagement with doctors assisted product development Development • Developed system fea
Slide 11: Breast Cancer - The Most Common Cancer in Women
Breast Cancer - The Most Common Cancer in Women 4 Stage Breast Cancer Trial at Hollywood Private Hospital (Western Australia’s largest) with Principal 2.1 Investigators Million new cancer cases (globally)1 Dr Peter Willsher, Breast Surgeon of the Breast Cancer Research Centre –WA Dr Jespal Gill, Ana
Slide 12: Optiscan Technology in Pre-clinical Market
Optiscan Technology in Pre-clinical Market Progress in the Preclinical market Research Applications with FIVE2 (ViewnVivo) ▪ Multiple trial demonstrations & funding ▪ Cancer research being sought by research institutions for potential purchase in Australia, North ▪ Tissue regeneration America and Ch
Slide 13: Investment Highlights
Investment Highlights • Optiscan system enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection • Collaboration with Carl Zeiss Meditech AG for Brain Cancer Surgical Device (US FDA and EU certifications already approved for use) and expected sales in first few mo